Jump to content

GlobeImmune initiates Phase IIa lung cancer trial


Recommended Posts

GlobeImmune initiates Phase IIa lung cancer trial

19th March 2008

By Staff Writer

GlobeImmune has started a Phase IIa clinical trial at Memorial Sloan Kettering Cancer Center to evaluate the company's GI-4000 Tarmogen for the treatment of non-small cell lung cancer patients with tumors having mutations in the ras gene.

GI-4000-03 is a an open-label consolidation therapy trial sponsored by Memorial Sloan Kettering Cancer Center (MSKCC) to evaluate the GI-4000 Tarmogen (targeted molecular immunogen) in subjects with non-small cell lung cancer (NSCLC) treated with curative intent, whose tumor is found to contain a mutation in the ras gene and who are disease free at their first post-treatment re-staging assessment (one-four months after completion of therapy).

The GI-4000-03 trial is designed to study safety, immune responses, and clinical benefit. Patients will receive GI-4000 for up to three years with the goal of delaying disease recurrence and prolonging survival.

Christopher Azzoli, principal investigator for the Phase IIa study at MSKCC, said: "MSKCC has a research program which treats NSCLC patients with adjuvant chemotherapy based on the results of a panel of molecular tests, including EGFR mutation status, ERCC1 expression levels, and ras mutation status. We are excited to explore the potential of GI-4000 to improve clinical outcomes in this difficult to treat patient population."

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.